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There are two challenges in vaginal drug delivery. First, the limited contact time cau-
sed by the physiological conditions imposed by the protective mechanisms of the vagina
(resulting in a frequent dosing regimen). The second challenge is patient compliance. Con-
ventional vaginal dosage forms such as ointments and inserts cause discomfort to the
patients (1). Although it is known that patients tolerate gels better than inserts or oint-
ments, direct application of gels into the vagina might be difficult as well as inconve-
nient (1). Recently, in situ gelling liquids have been investigated as a more convenient
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The purpose of this study was to develop pluronic-based
in situ gelling formulations of metronidazole (MTZ) for
treatment of bacterial vaginosis, aimed at prolonging the
residence time, controlling drug release, enhancing effi-
cacy, decreasing recurrence, and increasing patient com-
pliance. The in situ gel formulations were prepared us-
ing different concentrations of pluronic F-127 (PF-127) alo-
ne and in combination with pluronic F-68 (PF-68). The pre-
pared formulations were evaluated for their gelation tem-
perature (Tgel), in vitro drug release, rheological proper-
ties, mucoadhesion properties and tolerability by vaginal
mucosa in tissue levels. The Tgel decreased with in-
creasing PF-127 concentration. The Tgel was modulated
by addition of PF-68 to be within the acceptable range of
25–37 °C. With increasing pluronic concentration, the in
vitro drug release decreased, viscosity and mucoadhesi-
ve force increased. Histopathological examination of rab-
bit vaginas from the control and treated groups revealed
normal histology of the vagina and cervix. Based on the
in vitro evaluation of prepared formulations, the in situ
gelling liquid formulated with PF-127/PF-68 (20/10 %,
m/m) was selected for further clinical evaluation.
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dosage form for topical applications. The in situ forming hydrogels are stimuli-sensitive
hydrogels that exist as aqueous solutions before administration and immediately change
into standing gels after administration upon contact with the mucosa. The most com-
monly used thermoreversible gels are pluronics (2). The pluronic-based in situ gelling
dosage form is supposed to be easily applied and to give good spreading and coating of
the vagina, making the treatment more effective and probably result in prolonged effect
(1, 3).
Metronidazole (MTZ) was considered a drug of choice for treatment of bacterial va-
ginosis. Prolonged treatment was found to be the only effective solution to prevent the
high recurrence rate; however, such approach raises concerns about potential toxicity.
The objective of this study was to design a new vaginal thermosensitive in situ gel-
ling formulation with mucoadhesive properties.
EXPERIMENTAL
Materials
Metronidazole was generously donated by Nile Pharmaceuticals and Chemical In-
dustries Co. (Egypt). Pluronic F-127, Pluronic F-68, mucin powder and benzalkonium
chloride were purchased from Sigma Chemical Co. (USA). Sodium chloride, calcium hy-
droxide, potassium hydroxide, acetic acid, and glycerol were obtained from El-Nasr Com-
pany (Egypt). All the other chemicals were of pharmaceutical grade and were used as
received. The marketed preparation Tricho® 0.75 % (commercial MTZ vaginal gel) was
purchased from Chemical Industries Development (CID) Co., Egypt.
Preparation of pluronic gel formulations
Different concentrations of Pluronic F-127 alone or in combination with Pluronic F-68
were used in the preparation of in situ gelling liquids. Medicated in situ gelling liquids
were prepared on a mass basis using the modified cold method (4). Composition of the
prepared formulations is shown in Table I. For formulations F1 to F8, Pluronic F-127 or
combination of Pluronic F-127 and Pluronic F-68 were mixed and dissolved with 0.8 %
MTZ in cold citro-phosphate buffer of pH 4.5. Benzalkonium chloride, concentration 0.01
%, was used as preservative. Partially dissolved pluronic solutions were stored in a re-
frigerator at 4 °C overnight and stirred periodically until clear homogenous solutions
were obtained.
Gelation temperature (Tgel) measurement
Ten milliliters of cold sample solution (pluronic containing formula) were put into a
beaker (25 mL) placed in a low temperature water bath at room temperature. A ther-
mometer was immersed in the sample solution. The solution was heated at a constant
rate of 200 rpm under continuous stirring using a magnetic bar (Barnstead/Thermolyne,
USA). The temperature at which the magnetic bar stopped moving due to gelation was
reported as the gelation temperature (Tgel) (5). Each sample was measured in triplicate.
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Rheological studies
Rheological studies of the samples were carried out using a DV-III Ultra viscometer,
RV model, Brookfield, USA. Viscosity was measured at different temperatures of 4, 25
and 34 °C. The viscosity of each sample was determined before and after gelifying. Each
point is the mean of three readings.
Mucoadhesive force determination
Mucoadhesive forces of all the prepared formulations were determined using a mu-
coadhesive force measuring device, which is a modified balance. This balance was de-
veloped in our laboratory with slight modifications, according to the previously repor-
ted methods (6).
The mucoadhesive force of the formulations under examination was determined by
measuring the force required to detach the formulation from a mucin disc using the
measuring device. At the right arm of the balance, a mucin disc was horizontally glued
to the lower surface of the right pan of the modified balance. The mucin disc was hy-
drated with distilled water prior to the mucoadhesion test. Three drops of each formula
were placed on the upper surface of an inverted beaker, which was placed directly be-
low the right pan. The in situ forming liquid sample was exposed to a source of heat to
allow gelation. The upper stage of the modified balance containing the hydrated mucin
disc was adjusted to be in contact with the preparation. A preload of 10 grams was im-
mediately applied for 1 minute to ensure intimate contact between the mucin disc and
the sample and to allow formation of an adhesive bond. The preload time and the force
were kept constant for all the tested formulations. After completion of the preload time,
water was allowed to drip from the infusion set into a preweighed plastic jar placed on
the left pan of the balance at a constant rate of 5 mL per minute. The dripping of water
was stopped when the mucin disc was detached from the tested sample, the filled plas-
tic jar was reweighed and the mass of water required to detach the tested sample from
the mucin disc was calculated from the difference (7).
Measurements were repeated three times for each of the gel preparations, but a
fresh smooth gel surface was created before each measurement.
In vitro release of MTZ from in situ gelling formulations
In vitro release of MTZ from in situ gelling formulations was studied using a stan-
dard semi-permeable cellophane membrane. The release medium was a simulated vagi-
nal fluid (SVF). Simulated vaginal fluid was prepared as described (8). The pH of the
mixture was then adjusted to 4.5 using HCl. The membrane was firmly stretched over
one end of the glass tube (2.4 cm internal diameter) by means of a rubber band. One
gram of the tested formulation solution was weighed over the membrane in the dialysis
tube. The tube was suspended in a 250-mL glass cup containing 100 mL freshly prepared
release medium (SVF) (9). The experiment was carried out at constant temperature in a
shaking water bath previously adjusted to 37 ± 0.2 °C and 75 stroke per minute. Aliquots
(1 mL) were withdrawn from the release medium at each sampling time for up to 6 h
and 24 h in case of comparison with the marketed preparation. The aliquots were re-
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placed with an equal volume of the freshly prepared release medium kept at the same
temperature. The aliquots were diluted, and the amount of drug released was calculated
by measuring the absorbance at 320 nm against a blank (UV spectrophotometer, Jenway,
UK). The results were the mean of three runs. The release profile of MTZ was obtained
by plotting the % cumulative amount of drug released from each formulation against
time.
Histopathological study of vaginal tissues
Formula selection was done by screening all prepared formulations through the in
vitro histopathological characterization (10) for their tolerability by vaginal tissues. The
study obtained the approval from the Ethical Committee of the Faculty of Pharmacy,
Assiut University. Five adult female rabbits (weighing 1.5–2 kg) were used. F7 muco-
adhesive thermosensitive formulation was administered into the vagina (1 mL kg–1) for
three consecutive days. At 6 h post last dose, specimens from vagina and cervix were
isolated and fixed in 10 % neutral buffer formalin, dehydrated in a graded alcohol series,
cleared with methyl benzoate and embedded in paraffin wax. Four micron sections were
cut and stained with haematoxylin and eosin (HE) for histopathological examination by
light microscopy. Specimens from control rabbits (no gel administered to the vagina),
were similarly treated for comparison.
RESULTS AND DISCUSSION
MTZ concentration in all formulations was 0.8 % m/m and that of pluronics varied
0–30 % (Table I). Drug content uniformity of the prepared formulations ranged from 99.2
to 100.3 % of the labeled amount.
Gelation temperature (Tgel)
Tgel is the temperature at which the liquid phase makes a transition to gel. An ideal
in situ gel should be a free flowing liquid at room temperature so as to allow reproduci-
ble administration into the site of application where it undergoes in situ phase transition
to form a strong gel (11). The human vaginal temperature is 37.2 °C (12), so Tgel of vagi-
nal thermoreversible gels were considered to be suitable if they were in the range of
25–37 °C. If the Tgel is lower than 25 °C, a gel might be formed at room temperature,
leading to difficulties in manufacturing, handling, and administering. If Tgel is higher
than 37 °C, a liquid dosage form still exists at vaginal temperature, resulting in drainage
of the formula from the vagina at an early stage.
The data in Table I show that PF-127 alone at concentrations of 15, 20, 25 and 30 %
(F1–F4) gave Tgel higher than 40, 22, 18 and 10 °C, respectively. These gelation tempera-
tures are not within the suitable range. An increase in PF-127 concentration resulted in a
decrease in Tgel; this finding was in agreement with the data of Edsman et al. (13).
A modulation of Tgel to reach the desired range was achieved by using a combina-
tion of the two pluronics (grades F-127 and F-68).
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Effect of PF-68 addition on Tgel. – Tgel for PF-127 solutions and the solutions of
PF-127/PF-68 mixtures are shown in Table I. Formulations F5–F8 were found to gel be-
tween 25 and 37 °C, so they were considered to be suitable for vaginal application. Seve-
ral combinations of the two polymeric grades were tested and used in the formulation of
the in situ gelling liquids in order to select formulations having a suitable Tgel (Table II).
As shown in Tables I and II, the Tgel changed with the addition of PF-68 to 15 and 20 %
PF-127. The results showed that at constant PF-127 concentration, increasing the PF-68
concentration gradually increased the Tgel initially to a maximum, and then it decreased.
Maximum concentration of PF-68 was 10 %. Tgel decreased with further increment in PF-
-68 concentration. Similar results were previously reported (14).
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Table II. Effect of PF-68 on gelation temperature
PF-127 (15 %) PF-127 (20 %)
PF-68 (%) Tgel (ºC)a PF-68 (%) Tgel (ºC)
a
0 > 40 0 22 ± 0
3 > 40 3 25 ± 0
6 > 40 6 27 ± 1
10 > 40 10 28 ± 0
15 36 ± 1 15 27 ± 1
20 29 ± 1 20 22 ± 1
a Each value represents the mean ± SD of three experiments.






F1 15 – > 40
F2 20 – 22 ± 0
F3 25 – 18 ± 1
F4 30 – 10 ± 1
F5 15 15 36 ± 1
F6 15 20 29 ± 1
F7 20 10 28 ± 0
F8 20 15 27 ± 1
a Vehicle: citro-phosphate buffer pH 4.5.
b MTZ content in all formulations 0.8 % (m/m); content uniformity 99.2–100.3 %.
c Each value represents the mean ± SD of three experiments.
It is known that when the concentration and temperature of the polymer are above
a critical value, pluronic molecules in aqueous solution will self-assemble to form spheri-
cal micelles with a dehydrated polypropylene oxide (PPO) core surrounded by hydrated
swollen polyethylene oxide (PEO) chains (15). The thermoreversible gelation behavior is
accepted as a result of micellar entanglement and packing with the increase in tempera-
ture. Furthermore, it is generally accepted that the PPO, which is hydrophobic, has low-
ered Tgel and the PEO, which is hydrophilic, has increased Tgel. Therefore, a different
PEO/PPO ratio will lead to a different Tgel. The ratio of PEO/PPO in PF-127 is 7:3, while
in PF-68 it is 8:2. Thus, when a slight amount of PF-68 is added to a PF-127 solution, the
proportion of PEO increases, which leads to an increase in Tgel (11, 14). The possible rea-
son for Tgel decrease after a certain concentration of PF-68 (10 %) is that the incorpora-
tion of a small amount of PF-68 can only change the PEO/PPO ratio, causing an increase
in Tgel, while by increasing the PF-68 concentration sequentially, not only the PEO/PPO
ratio changes, but also the micellization of PF-68 molecules can participate in the con-
struction of the gel, which finally leads to a decrease in Tgel (14).
Rheological study
Rheological behavior is the key part in the formulation of PF-127 preparations. Ta-
ble III shows the viscosity of pluronic formulations at different PF-127 concentrations.
The same concentration of pluronic has different viscosity at different temperatures (4,
25, and 37 °C), where the viscosity increased with increasing temperature. This may be
attributed to the fact that pluronics, being non-ionic PPO triblock copolymers, aggregate
into micelles at 37 °C. This micellization is due to the dehydration of polymer blocks
with temperature. It has been shown that gel formation is a result of micellar enlarge-
ment and packing and that the gel is more entangled at higher PF-127 concentrations. As
a result of these micelle entanglements, they cannot separate easily from each other, which
accounts for the rigidity and high viscosity of gels containing high concentrations of plu-
ronics (15, 16).
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Table III. Viscosity and mucoadhesive force of pluronic formulations
Formula
code
Viscosity (mPa s) at temperature Mean mucoadhesive
force ´ 102 (N cm–2)a4 ºC 25 ºC 37 ºC
F1 0.00 66.7 21.6 ´ 103 –
b
F2 < 100 138.3 ´ 103 205.1 ´ 103 15.8 ± 0.4
F3 233 151.5 ´ 103 243 ´ 103 17.2 ± 2.5
F4 280 170 ´ 103 267.7 ´ 103 19.0 ± 3.7
F5 333.3 916.4 6.6 ´ 103 18.2 ± 2.5
F6 333 1.677 ´ 103 90.4 ´ 103 21.9 ± 0.4
F7 306 932 199.6 ´ 103 21.2 ± 1.4
F8 422 1.177 ´ 103 222.4 ´ 103 23.9 ± 0.4
a Mean ± SD, n = 3.
b Gelation temperature of F1 was > 40 °C, so it could not be handled during mucoadhesive force determina-
tion (it liquefied during the experiment).
Effect of PF-68 addition on viscosity. – Table III shows the results for the viscosity of
PF-127 formulations containing PF-68. Formulations composed of PF-127/PF-68 at con-
centrations 15/15 (%) (F5), 15/20 (%) (F6), 20/10 (%) (F7) and 20/15 (%) (F8) showed the
effect of PF-68 concentration on viscosity. The four formulations were liquid at 4 and 25
°C. At 4 °C, the four formulations did not show any notable change in viscosity. At 25
°C, formulation 15/20 (%) (F6) showed 1.8-fold higher viscosity compared to 15/15 (%)
(F5), but formulation 20/15 (%) (F8) showed 1.3-fold higher viscosity compared to for-
mulation 20/10 (%) (F7) at 25 °C. At 37 °C, formulations 15/20 (%) (F6) and 20/15 (%)
(F8) showed 14.4- and 1.1-fold higher viscosity than the other formulations, respectively.
This is attributed to the fact that the thickening power of pluronics in water increased
with the hydrophobic molecular mass and the ethylene oxide/propylene oxide ratios (17).
Mucoadhesive force determination
Mucoadhesive force is an important and crucial physicochemical parameter for in
situ forming vaginal gels since it prevents the formulation from rapid drainage and hen-
ce prolongs its residence time. Results of the determination of mucoadhesive forces of
all the formulations are collected in Table III. This table shows that the prepared MTZ in
situ gelling formulations with PF-127 possessed satisfactory adhesive properties. Increa-
sing the mucoadhesive polymer concentration significantly increased the mucoadhesive
force. Similar results were previously reported (18). The mucoadhesion rank order for
PF-127 formulations was 20 < 25 < 30 %.
Addition of PF-68, which is a homologene of PF-127, enhanced the bioadhesive force,
since the pluronic with a hydrophilic oxide group could bind to oligosaccharide chains.
The higher the concentration of PF-68, the greater the bioadhesive force of pluronic gels.
In vitro release of MTZ from in situ gelling formulations
Fig. 1 shows the cumulative amount of MTZ released vs. time profiles for various
drug-containing polymer solutions and the drug solution (control). All the polymer so-
lutions and the control contained 0.8 % (m/m) MTZ. For the drug solution, more than 90
% of MTZ was released after 1.5 h.
To study the effect of PF-127 concentration on drug release, the release of MTZ from
different PF-127 concentrations was investigated. Drug concentration (0.8 %, m/m) and
the temperature 37 ± 0.2 °C were kept constant, while the PF-127 concentration was var-
ied (20, 25 and 30 %). The results show that as the concentration of PF-127 increased
from 20 to 30 %, the amount of drug released decreased. This indicates that the structure
of the gel functioned as an increasingly resistant barrier to drug release as the concentra-
tion of PF-127 increased. Such enhanced resistance may be due to the reduction in the
number and dimension of water channels and to the increase in the number and size of
micelles within the gel structure. Shorter intermicellar distance leads to a larger number
of cross-links between neighboring micelles, leading to higher viscosity and lower rate
of drug release (19). This assumption may be potentiated by the rheology study. From
the rheological study, it was observed that there is an inversely proportional relationship
between MTZ viscosity and release rate.
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Effect of PF-68 on the release rate
To study the effect of PF-68 on the release rate of MTZ from the pluronic-based in
situ gelling formulations, a release test was performed using the formulations composed
of a constant concentration of PF-127 (15 or 20 %, m/m) and variable concentrations of
PF-68. PF-68 showed little effect on the release rate of MTZ from in situ gelling formula-
tions. As shown in Fig. 1, the addition of 20 % PF-68 to 15 % PF-127 (F6) resulted in a
slight decrease in the release rate compared to 15 % PF-68 (F5). In case of 20 % PF-127,
the addition of 10 % (F7) and 15 % PF-68 (F8) showed a very low reduction in the release
rate. This slight decrease in the release rate may be attributed to the increase in viscosity.
The formula suggested for clinical study was F7 based on Tgel, which was consi-
dered an important parameter. The formulations with suitable Tgel were F5, F6, F7, and
F8. The rank order for drug release was F5 > F6 > F7  F8. Thus, the final choice between
F7 and F8 depended on the viscosity, mucoadhesion and the total concentration of the
two pluronics. Table IV shows that the difference between F7 and F8 regarding viscosity
and mucoadhesion was very small. Either of the two formulations could be used, so the
formula that contained smaller concentration of pluronic (20/10 %) was recommended
(F7). F7 was easier to be prepared than F8.
66
E. S. A. Ibrahim et al.: Development and characterization of thermosensitive pluronic-based metronidazole in situ gelling formulations
for vaginal application, Acta Pharm. 62 (2012) 59–70.
Table IV. Viscosity and mucoadhesion difference between F7, F8 and Tricho® gel
Formula code
Viscosity (mPa s) Bioadhesive force
´ 102 (N cm–2)a4 ºC 25 ºC 37 ºC
F7 306 932 199.6 ´ 103 21.2 ± 1.4
F8 422 1177.7 222.4 ´ 103 23.9 ± 0.4
Tricho® gel 153.5 ´ 103 156 ´ 103 156.1 ´ 103 11.3 ± 3.4



























Fig. 1. Effect of concentrations of PF-127 alone and PF-127/PF-68 combinations on the release pro-
file of MTZ from in situ gelling formulations (SEM bars, n = 3).
Histopathological study of vaginal tissues
Histopathological examinations from the control group and from the treated group
(after using formulation F7) revealed normal histology of the vagina and cervix (Fig. 2).
It was reported that thermosensitive gel vehicles, which were composed mainly of plu-
ronics (PF-127 and PF-68), did not influence the viability of the cells and did not alter the
morphology of vaginal tissues, i.e., there was no visible sign of inflammation or necrosis
(1).
Comparison of MTZ release from the selected in situ gelling formula (F7) and the
marketed gel (Tricho® gel)
We compared our formula to the marketed formulation already in use regarding sus-
tained release, viscosity and mucoadhesion as the basis for our clinical study.
It was found that the release from MTZ in situ gelling formulation F7 was slower
than that from the marketed gel (Tricho® gel). After 6 h, the percent drug released form
Tricho® gel was 91 %, while the percentage released from F7 was 76 % (Fig. 3a). Fig. 3b
shows that the drug was completely released from Tricho® gel after 12 h, while 90 %
MTZ was released from F7 after the same period. These in vitro results suggest that plu-
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Fig. 2. a) Vagina of control rabbits showing normal epithelial lining, b) cervix of control rabbits show-
ing normal epithelial lining, c) vagina of metronidazole treated rabbits (F7 formulation) showing
normal epithelial lining, d) cervix of metronidazole (F7 formulation) treated rabbits showing nor-
mal epithelial lining (magnification 40´).
ronic formulations might serve as a rate-controlling barrier and can be useful as a vehi-
cle for sustained release preparations of MTZ.
The differences between formulation F7 and Tricho® gel in viscosity and mucoad-
hesion are summarized in Table IV. Viscosity of Tricho® gel did not change with tempera-
ture increase. In contrast to Tricho® gel, the free flowing property of formula F7 would
enable the patient to apply the required dose accurately and would result in good sprea-
ding and coating of the vagina. At 37 °C, the viscosity of F7 was higher than that of Tri-
cho® gel. Table IV shows that the mucoadhesion expressed as detachment force of for-
mula F7 and Tricho® gel were 0.2116 and 0.1133 N cm–2, respectively. Based on these
results, it is expected that formula F7 will be retained on vaginal mucosal tissue for a
longer period than the Tricho® gel.
Clinical evaluation of formula F7 in comparison with the marketed preparation (Tri-
cho® gel) in patients with bacterial vaginosis (20) showed that the cure rate after one
week of treatment was 85 % in the in situ gel F7 group and 71 % in the conventional vag-
inal gel group (Tricho® gel), while after 4 weeks, the cure rate showed a significant
difference in the in situ gel group compared to the conventional vaginal gel group (80
versus 47 %, respectively, p = 0.034). This shows that the in situ MTZ vaginal gel F7 is
more effective than the conventional vaginal gel product for sustained cure of bacte-
rial vaginosis.
CONCLUSIONS
The in situ gelling liquids are considered a more convenient formulation for topical
application into the vagina. Formula F7 was the most suitable of pluronic formulations.
It showed appropriate viscosity, mucoadhesion, delayed release and Tgel within the suit-
able range. From the release and mucoadhesion studies, it was found that the in situ gel
formula will be retained in the vagina for a longer period than Tricho® gel. Histopatho-
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Fig. 3. Comparison of MTZ release from formulation F7 and the marketed preparation (Tricho
® gel)
after: a) 6 h and b) 24 h (SEM bars, n = 3).
logical examination of vaginal and cervical sections from the control and MTZ treated
groups revealed normal histology. Hence, the use of this formulation is expected to ma-
ke the treatment more effective as it gives good spreading and coating properties of the
vagina, which was confirmed by the clinical study conducted later on.
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S A @ E T A K
Razvoj i karakterizacija in situ geliraju}ih pripravaka metronidazola
na bazi pluronika za vaginalnu primjenu
EL-SAYED ALI IBRAHIM, SAYED ISMAIL, GIHAN FETIH, OMAR SHAABAN,
KHALED HASSANEIN i NOURA HASSAN ABDELLAH
Cilj rada bio je razviti pripravke metronidazola (MTZ) za lije~enje bakterijske vagi-
noze koji imaju sposobnost geliranja in situ, produljeno vrijeme zadr`avanja na mjestu
primjene, kontrolirano osloba|anje ljekovite tvari, pove}anu u~inkovitost te smanjiti po-
novnu pojavu vaginoze i pove}ati suradljivost pacijenta. Pripravci koji geliraju in situ
pripravljeni su koriste}i razli~ite koncentracije pluronika F-127 (PF-127), samog ili u
kombinaciji s pluronikom F-68 (PF-68). Ispitivana je temperatura geliranja (Tgel) formu-
lacija, in vitro osloba|anje ljekovite tvari, reolo{ka svojstva, mukoadhezijska svojstva te
kako ih podna{a vaginalna sluznica u slojevima tkiva. Uo~eno je da se s pove}anjem
koncentracije PF-127 sni`ava Tgel. Dodatkom razli~itih koli~ina PF-68 dobiveni su pri-
pravci s rasponom Tgel od 25 do 37 ºC. S pove}anjem koncentracije pluronika smanjilo se
osloba|anje ljekovite tvari in vitro, a pove}ala se viskoznost i mukoadhezivnost. Histo-
patolo{ka ispitivanja na ze~icama ispitivane i kontrolne skupine dala su normalni histo-
lo{ki nalaz njihovih vagina i cerviksa. Na temelju in vitro evaluacije, formulacija s PF-127/
PF-68 (20/10 %, m/m) izabrana je za daljnja klini~ka ispitivanja.
Klju~ne rije~i: metronidazol, in situ geliranje, mukoadhezija, pluronici
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